second generation antidepressive agents

Summary

Summary: A structurally and mechanistically diverse group of drugs that are not tricyclics or monoamine oxidase inhibitors. The most clinically important appear to act selectively on serotonergic systems, especially by inhibiting serotonin reuptake.

Top Publications

  1. ncbi [Safety of selective serotonin reuptake inhibitor antidepressants in children and adolescents]
    Daniel Bailly
    service hospitalo universitaire de psychiatrie, Hopital Sainte Marguerite, Marseille 13
    Presse Med 35:1507-15. 2006
  2. doi Serum concentrations of nerve growth factor and brain-derived neurotrophic factor in depressed patients before and after antidepressant treatment
    R Hellweg
    Central Institute of Mental Health, Mannheim, Germany
    Pharmacopsychiatry 41:66-71. 2008
  3. ncbi The effect of citalopram pretreatment on neuronal responses to neuropsychological tasks in normal volunteers: an FMRI study
    Cristina M Del-Ben
    Faculty of Medicine of Ribeirao Preto, University of Sao Paulo, Ribeirao Preto, Brazil
    Neuropsychopharmacology 30:1724-34. 2005
  4. ncbi Efficacy of cognitive behavioral therapy and fluoxetine for the treatment of binge eating disorder: a randomized double-blind placebo-controlled comparison
    Carlos M Grilo
    Department of Psychiatry, Yale University School of Medicine, New Haven, Connecticut 06520, USA
    Biol Psychiatry 57:301-9. 2005
  5. doi The antidepressant fluoxetine restores plasticity in the adult visual cortex
    José Fernando Maya Vetencourt
    Scuola Normale Superiore, Piazza dei Cavalieri, I 56100 Pisa, Italy
    Science 320:385-8. 2008
  6. pmc Modeling of the temporal patterns of fluoxetine prescriptions and suicide rates in the United States
    Michael S Milane
    Center for Pharmacogenomics and Clinical Pharmacology, Semel Institute for Neuroscience and Human Behavior, University of California Los Angeles, Los Angeles, California, USA
    PLoS Med 3:e190. 2006
  7. ncbi Chronic antidepressant treatment induces contrasting patterns of synaptophysin and PSA-NCAM expression in different regions of the adult rat telencephalon
    E Varea
    Neurobiology Unit and Program in Basic and Applied Neurosciences, Cell Biology Department, Universitat de Valencia, Spain
    Eur Neuropsychopharmacol 17:546-57. 2007
  8. ncbi Citalopram modulation of neuronal responses to aversive face emotions: a functional MRI study
    Ian M Anderson
    Neuroscience and Psychiatry Unit, The University of Manchester, Stopford Building, Oxford Road, Manchester, UK
    Neuroreport 18:1351-5. 2007
  9. ncbi Incidence and duration of antidepressant-induced nausea: duloxetine compared with paroxetine and fluoxetine
    John Greist
    Healthcare Technology Systems, Madison, Wisconsin 53717, USA
    Clin Ther 26:1446-55. 2004
  10. ncbi Venlafaxine in treatment-resistant major depression: a Canadian multicenter, open-label trial
    C de Montigny
    Department of Psychiatry, McGill University, Montreal, Quebec, Canada
    J Clin Psychopharmacol 19:401-6. 1999

Detail Information

Publications201 found, 100 shown here

  1. ncbi [Safety of selective serotonin reuptake inhibitor antidepressants in children and adolescents]
    Daniel Bailly
    service hospitalo universitaire de psychiatrie, Hopital Sainte Marguerite, Marseille 13
    Presse Med 35:1507-15. 2006
    ..Their use should be reserved for severe disorders or when psychotherapy alone has been shown to be inadequate, and when they are used, efficacy and side effects must be monitored carefully and frequently...
  2. doi Serum concentrations of nerve growth factor and brain-derived neurotrophic factor in depressed patients before and after antidepressant treatment
    R Hellweg
    Central Institute of Mental Health, Mannheim, Germany
    Pharmacopsychiatry 41:66-71. 2008
    ..Recent research suggests that serum BDNF concentration is reduced in depression and that successful antidepressant treatment leads to an increase in serum BDNF concentration...
  3. ncbi The effect of citalopram pretreatment on neuronal responses to neuropsychological tasks in normal volunteers: an FMRI study
    Cristina M Del-Ben
    Faculty of Medicine of Ribeirao Preto, University of Sao Paulo, Ribeirao Preto, Brazil
    Neuropsychopharmacology 30:1724-34. 2005
    ..The technique of combining drug challenge with fMRI (pharmacoMRI) has promise for investigating human psychiatric disorders...
  4. ncbi Efficacy of cognitive behavioral therapy and fluoxetine for the treatment of binge eating disorder: a randomized double-blind placebo-controlled comparison
    Carlos M Grilo
    Department of Psychiatry, Yale University School of Medicine, New Haven, Connecticut 06520, USA
    Biol Psychiatry 57:301-9. 2005
    ..We conducted a randomized, placebo-controlled study to test the efficacy of CBT and fluoxetine alone and in combination for BED...
  5. doi The antidepressant fluoxetine restores plasticity in the adult visual cortex
    José Fernando Maya Vetencourt
    Scuola Normale Superiore, Piazza dei Cavalieri, I 56100 Pisa, Italy
    Science 320:385-8. 2008
    ..Our results suggest a potential clinical application for fluoxetine in amblyopia as well as new mechanisms for the therapeutic effects of antidepressants and for the pathophysiology of mood disorders...
  6. pmc Modeling of the temporal patterns of fluoxetine prescriptions and suicide rates in the United States
    Michael S Milane
    Center for Pharmacogenomics and Clinical Pharmacology, Semel Institute for Neuroscience and Human Behavior, University of California Los Angeles, Los Angeles, California, USA
    PLoS Med 3:e190. 2006
    ....
  7. ncbi Chronic antidepressant treatment induces contrasting patterns of synaptophysin and PSA-NCAM expression in different regions of the adult rat telencephalon
    E Varea
    Neurobiology Unit and Program in Basic and Applied Neurosciences, Cell Biology Department, Universitat de Valencia, Spain
    Eur Neuropsychopharmacol 17:546-57. 2007
    ..The expression of these molecules is also affected in the entorhinal, the visual and the somatosensory cortices...
  8. ncbi Citalopram modulation of neuronal responses to aversive face emotions: a functional MRI study
    Ian M Anderson
    Neuroscience and Psychiatry Unit, The University of Manchester, Stopford Building, Oxford Road, Manchester, UK
    Neuroreport 18:1351-5. 2007
    ..No citalopram modulation of BOLD responses to angry faces were found. These results suggest that serotonin modulates low-level amygdala activation to aversive stimuli...
  9. ncbi Incidence and duration of antidepressant-induced nausea: duloxetine compared with paroxetine and fluoxetine
    John Greist
    Healthcare Technology Systems, Madison, Wisconsin 53717, USA
    Clin Ther 26:1446-55. 2004
    ..This analysis assessed the incidence, severity, onset, and duration of nausea among patients with major depressive disorder (MDD) treated with the new antidepressant duloxetine...
  10. ncbi Venlafaxine in treatment-resistant major depression: a Canadian multicenter, open-label trial
    C de Montigny
    Department of Psychiatry, McGill University, Montreal, Quebec, Canada
    J Clin Psychopharmacol 19:401-6. 1999
    ..In conclusion, these results suggest that venlafaxine is effective and well tolerated for the management of patients with treatment-resistant major depression...
  11. ncbi CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment
    Yan Jin
    Division of Clinical Pharmacology, Department of Medicine, Indiana University School of Medicine, Indianapolis, IN 46202, USA
    J Natl Cancer Inst 97:30-9. 2005
    ....
  12. ncbi Fluoxetine and norfluoxetine stereospecifically and selectively increase brain neurosteroid content at doses that are inactive on 5-HT reuptake
    Graziano Pinna
    Psychiatric Institute, Department of Psychiatry, College of Medicine, University of Illinois at Chicago, 1601 W Taylor Street, Chicago, IL 60612, USA
    Psychopharmacology (Berl) 186:362-72. 2006
    ..Therefore, the term "SSRI" may be misleading in defining the pharmacological profile of fluoxetine and its congeners. To this extent, the term "selective brain steroidogenic stimulants" (SBSSs) could be proposed...
  13. ncbi Managing depressive and anxiety disorders with escitalopram
    Michael E Thase
    University of Pittsburgh Medical Centre, Western Psychiatric Institute and Clinic, Pittsburgh, PA 15213 2593, USA
    Expert Opin Pharmacother 7:429-40. 2006
    ..Pharmacoeconomic models suggest that the greater drug acquisition cost of this patent-protected compound may be offset by greater efficacy (relative to generic citalopram) and tolerability (compared with extended release venlafaxine)...
  14. ncbi The selective serotonin reuptake inhibitor citalopram increases fear after acute treatment but reduces fear with chronic treatment: a comparison with tianeptine
    Nesha S Burghardt
    W M Keck Foundation Laboratory of Neurobiology, Center for Neural Science, New York University, New York, New York 10003, USA
    Biol Psychiatry 55:1171-8. 2004
    ..In this study, we used fear conditioning to begin to understand how acute and chronic SSRI treatment might differentially affect well-characterized fear circuits...
  15. ncbi Does concurrent prescription of selective serotonin reuptake inhibitors and non-steroidal anti-inflammatory drugs substantially increase the risk of upper gastrointestinal bleeding?
    L J Tata
    Epidemiology and Public Health, University of Nottingham, City Hospital, Nottingham, UK
    Aliment Pharmacol Ther 22:175-81. 2005
    ..Recent guidance cautions against concurrent prescription, particularly in older people...
  16. ncbi Efficacy and safety of second-generation antidepressants in the treatment of major depressive disorder
    Richard A Hansen
    Division of Pharmaceutical Policy and Evaluative Sciences, University of North Carolina, Chapel Hill, North Carolina 27599, USA
    Ann Intern Med 143:415-26. 2005
    ....
  17. ncbi Escitalopram (10-20 mg/day) is effective and well tolerated in a placebo-controlled study in depression in primary care
    Ulla M Lepola
    Kuopion Psykiatripalvelu OY Psychiatric Research, Clinic of Kuopio, Kuopio, Finland
    Int Clin Psychopharmacol 18:211-7. 2003
    ..This study demonstrates the consistent antidepressant efficacy and excellent tolerability of escitalopram 10-20 mg/day in primary care patients with major depressive disorder...
  18. ncbi Bupropion extended release compared with escitalopram: effects on sexual functioning and antidepressant efficacy in 2 randomized, double-blind, placebo-controlled studies
    Anita H Clayton
    Department of Psychiatric Medicine, University of Virginia Health System, Charlottesville, USA
    J Clin Psychiatry 67:736-46. 2006
    ..To compare the effects on sexual functioning and the antidepressant efficacy of once-daily bupropion extended release (XL) and escitalopram in adults with major depressive disorder (MDD)...
  19. ncbi Comparative toxicity of citalopram and the newer antidepressants after overdose
    C A Kelly
    Scottish Poisons Information Bureau, Royal Infirmary, Little France Crescent, Edinburgh, Scotland, UK
    J Toxicol Clin Toxicol 42:67-71. 2004
    ..To compare the toxicity of citalopram, venlafaxine, mirtazapine, and nefazadone after overdose...
  20. doi Repetitive transcranial magnetic stimulation (rTMS) in combination with escitalopram in patients with treatment-resistant major depression: a double-blind, randomised, sham-controlled trial
    L G Bretlau
    Psychiatric Research Unit, Frederiksborg General Hospital, Hillerød, Denmark
    Pharmacopsychiatry 41:41-7. 2008
    ..However, because a recent meta-analysis showed only a small effect size of rTMS over sham TMS in the acute treatment phase of depressed patients, we decided to make an interim analysis...
  21. ncbi Frequency of provider contact after FDA advisory on risk of pediatric suicidality with SSRIs
    Elaine H Morrato
    University of Colorado, Denver, CO 80262, USA
    Am J Psychiatry 165:42-50. 2008
    ..In this study, the authors compared trends in the frequency of provider contacts for patients with depression before and after the advisory was issued...
  22. ncbi Up-regulation of tryptophan hydroxylase-2 mRNA in the rat brain by chronic fluoxetine treatment correlates with its antidepressant effect
    G T Shishkina
    Functional Neurogenomics Laboratory, Institute of Cytology and Genetics, Russian Academy of Science, Novosibirsk 630090, Russia
    Neuroscience 150:404-12. 2007
    ..The results of the present study suggest that TPH2 gene expression in the midbrain part of the DRN is implicated in depression and stress response, as well as in the antidepressant fluoxetine action...
  23. ncbi Which antidepressants have demonstrated superior efficacy? A review of the evidence
    Stuart A Montgomery
    Imperial College School of Medicine, University of London, UK
    Int Clin Psychopharmacol 22:323-9. 2007
    ..This review of published data found evidence that only a very few antidepressants are shown to be more effective than others...
  24. ncbi Fluoxetine vs placebo for depressive symptoms after stroke: failed randomised controlled trial
    M Ruddell
    Faculty of Medicine and Health, University of Leeds
    Int J Geriatr Psychiatry 22:963-5. 2007
    ..In stroke care, the evidence of effectiveness from systematic reviews is surprisingly weak. We therefore decided to undertake a randomised controlled trial comparing fluoxetine to placebo...
  25. ncbi Proteomic analysis of rat cortical neurons after fluoxetine treatment
    Daniela Cecconi
    Department of Agricultural and Industrial Biotechnologies, University of Verona, Italy
    Brain Res 1135:41-51. 2007
    ....
  26. ncbi Prevalence of risk factors for suicide in patients prescribed venlafaxine, fluoxetine, and citalopram
    Daniel Mines
    Global Safety Surveillance and Epidemiology, Wyeth Research, Collegeville, PA 19426 3930, USA
    Pharmacoepidemiol Drug Saf 14:367-72. 2005
    ..It is not clear whether patient factors could account for this finding. We evaluated whether risk factors for suicide are more prevalent among patients prescribed venlafaxine than patients prescribed fluoxetine or citalopram...
  27. ncbi Remission from depression : a review of venlafaxine clinical and economic evidence
    Donald Han
    Wyeth Pharmaceuticals, Markham, Ontario, Canada
    Pharmacoeconomics 23:567-81. 2005
    ..The availability of an effective armamentarium of antidepressant strategies, including venlafaxine, to achieve and sustain remission offers both clinical and economic value to all those touched by the burden of depression...
  28. ncbi Therapeutic options for sleep-maintenance and sleep-onset insomnia
    Anna K Morin
    Department of Pharmacy Practice, Massachusetts College of Pharmacy and Health Sciences, Worcester, Massachusetts 01608 1715, USA
    Pharmacotherapy 27:89-110. 2007
    ..All pharmacotherapy should be used with appropriate caution, at minimum effective doses, and for minimum duration of time...
  29. ncbi Genotype-dependent activity of tryptophan hydroxylase-2 determines the response to citalopram in a mouse model of depression
    Luigi Cervo
    Department of Neuroscience, Istituto di Ricerche Farmacologiche Mario Negri, 20157 Milan, Italy
    J Neurosci 25:8165-72. 2005
    ..Interstrain comparisons could probably be a useful strategy for understanding the mechanisms underlying the response to selective serotonin reuptake inhibitors...
  30. ncbi Chronic fluoxetine treatment attenuates stressor-induced changes in temperature, heart rate, and neuronal activation in the olfactory bulbectomized rat
    Michelle Roche
    Department of Pharmacology, National University of Ireland, Galway, Galway, Ireland
    Neuropsychopharmacology 32:1312-20. 2007
    ..These results identify stress-sensitive regions within the brain which are altered following bulbectomy and which may underlie the abnormal behavioral and physiological changes observed in this rodent model of depression...
  31. ncbi Biphasic change in BDNF gene expression following antidepressant drug treatment explained by differential transcript regulation
    A A Khundakar
    Leicester School of Pharmacy, Faculty of Health and Life Sciences, De Montfort University, The Gateway, Leicester, LE1 9BH, UK
    Brain Res 1106:12-20. 2006
    ..In summary, this study shows clear evidence of differential BDNF transcript regulation following acute and chronic antidepressant drug treatment...
  32. ncbi Lack of attenuation in the antitumor effect of tamoxifen by chronic CYP isoform inhibition
    David Lehmann
    SUNY Upstate Medical University, Syracuse, USA
    J Clin Pharmacol 44:861-5. 2004
    ....
  33. ncbi Escitalopram continuation treatment prevents relapse of depressive episodes
    Mark Hyman Rapaport
    Department of Psychiatry, Cedars Sinai Medical Center, Los Angeles, CA 90048, USA
    J Clin Psychiatry 65:44-9. 2004
    ..Current guidelines for antidepressant use recommend 4 to 6 months of continuation treatment to prevent relapse of depression following symptom resolution. This study evaluates the efficacy and safety of continuation escitalopram treatment...
  34. ncbi Cost effectiveness of fluvoxamine in the treatment of recurrent depression in France
    M Nuijten
    Lewin Group, Hoofddorp, The Netherlands
    Pharmacoeconomics 14:433-45. 1998
    ..The objective of this study was to examine the cost effectiveness of fluvoxamine compared with tricyclic antidepressants (TCAs) in the treatment of patients with depressive episodes...
  35. pmc Quality of life and metabolic status in mildly depressed women with type 2 diabetes treated with paroxetine: a single-blind randomised placebo controlled trial
    Maria Paile-Hyvärinen
    Department of Psychiatry, University of Helsinki, Lapinlahti Hospital, P O Box 320, FIN 00029 HUCH, Helsinki, Finland
    BMC Fam Pract 4:7. 2003
    ..The aim of this trial was to evaluate the effect of the antidepressant paroxetine on metabolic control, quality of life and mental well-being in mildly depressed women with type 2 diabetes...
  36. ncbi Diphenhydramine alters the disposition of venlafaxine through inhibition of CYP2D6 activity in humans
    E Lessard
    Quebec Heart Institute, Laval Hospital, Canada
    J Clin Psychopharmacol 21:175-84. 2001
    ..Clinically significant interactions could be encountered during the concomitant administration of diphenhydramine and other antidepressant or antipsychotic drugs that are substrates of CYP2D6...
  37. ncbi Fluvoxamine but not citalopram increases serum melatonin in healthy subjects-- an indication that cytochrome P450 CYP1A2 and CYP2C19 hydroxylate melatonin
    C von Bahr
    Karolinska Institutet, Department of Medicine, Stockholm Soder Hospital, Sweden
    Eur J Clin Pharmacol 56:123-7. 2000
    ..If FLU, but not CIT, inhibits liver enzymes involved in the metabolism of MT, different serum MT concentrations should probably ensue. The objective of this investigation was to test this hypothesis...
  38. ncbi Effect of venlafaxine versus fluoxetine on metabolism of dextromethorphan, a CYP2D6 probe
    J Amchin
    Wyeth-Ayerst Laboratories, 240 North Radnor-Chester Road, St. Davids, PA 19087, USA
    J Clin Pharmacol 41:443-51. 2001
    ..This suggests that clinically significant interactions involving CYP2D6 inhibition could occur between fluoxetine and drugs metabolized by CYP2D6 but may be less likely to occur with venlafaxine...
  39. ncbi Sociological influences on antidepressant prescribing
    Betsy Sleath
    School of Pharmacy and Cecil G Sheps Center for Health Services Research, University of North Carolina at Chapel Hill, Beard Hall CB 7360, Chapel Hill, NC 27599 7360, USA
    Soc Sci Med 56:1335-44. 2003
    ..Health care providers need to take the time to help patients without insurance obtain antidepressant medication if it is needed...
  40. ncbi Venlafaxine in management of hot flashes in survivors of breast cancer: a randomised controlled trial
    C L Loprinzi
    Mayo Clinic and Mayo Foundation, Rochester, MN 55905, USA
    Lancet 356:2059-63. 2000
    ..We undertook a double-blind, placebo-controlled, randomised trial to assess the efficacy of venlafaxine in women with a history of breast cancer or reluctance to take hormonal treatment because of fear of breast cancer...
  41. ncbi Duloxetine Eli Lilly & Co
    N Pitsikas
    Boehringer Ingelheim, Via Lorenzini 8, Milan 20139, Italy
    Curr Opin Investig Drugs 1:116-21. 2000
    ..In August 1999, this prediction changed, and the expected launch date became 2001, with an 80% probability of reaching the market and sales peaking at US $150 million in 2012 [349228]...
  42. ncbi Differential effects of fluvoxamine and other antidepressants on the biotransformation of melatonin
    S Hartter
    Department of Psychiatry, University of Mainz, Germany
    J Clin Psychopharmacol 21:167-74. 2001
    ..Because this inhibitory action is also found in vivo, fluvoxamine might be used as an enhancer of melatonin, which might offer new therapeutic possibilities of fluvoxamine...
  43. ncbi Mirtazapine versus venlafaxine in hospitalized severely depressed patients with melancholic features
    J D Guelfi
    Hĵpital Paul Brousse, Villejuif, France
    J Clin Psychopharmacol 21:425-31. 2001
    ..In this study, treatment with mirtazapine resulted in a trend toward more responders and remitters than treatment with venlafaxine and in significantly fewer dropouts as a result of adverse events...
  44. ncbi A placebo-controlled comparison of the effects on sexual functioning of bupropion sustained release and fluoxetine
    C C Coleman
    Mississippi Neuropsychiatric Clinic, Paragon Center, Ridgeland 39157, USA
    Clin Ther 23:1040-58. 2001
    ..Fluoxetine, however, was more frequently associated with sexual dysfunction compared with bupropion SR. Bupropion SR may be an appropriate initial choice for the treatment of depression in patients concerned about sexual functioning...
  45. ncbi Duloxetine in the acute and long-term treatment of major depressive disorder: a placebo- and paroxetine-controlled trial
    Michael J Detke
    Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285, USA
    Eur Neuropsychopharmacol 14:457-70. 2004
    ..This placebo-controlled study assesses the safety and efficacy of duloxetine (80 or 120 mg/day) and paroxetine (20 mg QD) during an initial 8-week acute phase and subsequent 6-month continuation phase treatment of MDD...
  46. ncbi Bupropion enhances brain reward function and reverses the affective and somatic aspects of nicotine withdrawal in the rat
    John F Cryan
    Department of Neuropharmacology, CVN 7, The Scripps Research Institute, 10550 North Torrey Pines Road, La Jolla, CA 92037, USA
    Psychopharmacology (Berl) 168:347-58. 2003
    ..Bupropion is an atypical antidepressant and the only non-nicotine-based therapy approved for smoking cessation. Its use has raised much debate as to how a non-nicotine-based agent can aid in smoking cessation...
  47. ncbi Combined treatment with haloperidol and trazodone in patients with tic disorders
    L Saccomani
    Child Neuropsychiatry, DSNV, G Gaslini Institute, University of Genova, Italy
    J Child Adolesc Psychopharmacol 10:307-10. 2000
    ..001) between the baseline and endpoint treatment conditions. This approach significantly reduces clinical symptoms, with the advantage of a lower dose of haloperidol than usual, with no side effects reported by the patients...
  48. ncbi Bupropion hydrochloride produces conditioned hyperactivity in rats
    Jamie L Wilkinson
    University of Nebraska Lincoln, Department of Psychology, United States
    Physiol Behav 90:790-6. 2007
    ..However, a predictive relation between reactivity to forced novelty and the subsequent locomotor effect of bupropion may not be one of these similarities...
  49. ncbi Repetitive transcranial magnetic stimulation does not potentiate antidepressant treatment
    E Poulet
    EA 3092, Universite Claude Bernard Lyon 1, 69677 Bron Cedex, France
    Eur Psychiatry 19:382-3. 2004
    ..Both groups had the same delay in scale's scores improvement. rTMS seems not to be efficient as an add-on treatment to pharmacological medication in non-resistant major depression...
  50. ncbi Altered brain activation pattern associated with drug-induced attenuation of enhanced depression-like behavior in rats bred for high anxiety
    Patrik Muigg
    Department of Pharmacology and Toxicology, University of Innsbruck, Innsbruck, Austria
    Biol Psychiatry 61:782-96. 2007
    ..The aim of the present study was to identify neuronal substrates underlying this treatment response in HABs...
  51. ncbi Venlafaxine treatment of binge-eating disorder associated with obesity: a series of 35 patients
    Shishuka Malhotra
    Department of Psychiatry, University of Cincinnati Medical Center, Ohio 45267 0559, USA
    J Clin Psychiatry 63:802-6. 2002
    ....
  52. ncbi Are the newer antidepressant drugs as effective as established physical treatments? Results from an Australasian clinical panel review
    G Parker
    School of Psychiatry, University of New South Wales, Randwick, Australia
    Aust N Z J Psychiatry 33:874-81. 1999
    ....
  53. pmc Suicide rates and antidepressant prescribing: a casual or causal relationship?
    Bernhard Baune
    Discipline of Psychiatry, School of Medicine, James Cook University, Queensland, Australia
    PLoS Med 3:e220. 2006
  54. ncbi Effects of paroxetine and venlafaxine XR on heart rate variability in depression
    Jonathan Davidson
    Department of Psychiatry and Behavioral Sciences, Duke University Medical Center, Durham, NC 27710, USA
    J Clin Psychopharmacol 25:480-4. 2005
    ..Further comparisons of selective serotonin reuptake inhibitor and serotonin and norepinephrine reuptake inhibitor drugs on HRV are warranted...
  55. pmc Risk of suicide during treatment with venlafaxine, citalopram, fluoxetine, and dothiepin: retrospective cohort study
    Annalisa Rubino
    RTI Health Solutions, Manchester Science Park, Manchester M15 6SE
    BMJ 334:242. 2007
    ..To compare the risk of suicide in adults using the antidepressant venlafaxine compared with citalopram, fluoxetine, and dothiepin...
  56. ncbi The selective serotonin reuptake inhibitors controversy in the treatment of depression in children
    Elizabeth B Weller
    Curr Psychiatry Rep 7:87-90. 2005
    ..Therefore, a reduction in the use of SSRIs in children and adolescents should be considered carefully...
  57. ncbi Hypertensive crisis associated with venlafaxine
    Rahul N Khurana
    Am J Med 115:676-7. 2003
  58. ncbi Cardiovascular effects of fluvoxamine and maprotiline in depressed patients
    W Hewer
    Neurobiology Unit, Central Institute of Mental Health, Mannheim, Germany
    Eur Arch Psychiatry Clin Neurosci 246:1-6. 1995
    ..Although these effects were not clinically relevant in our sample of patients without overt heart disease, they should be taken into account when treating depressed patients with concomitant cardiac disease...
  59. ncbi The treatment of major depressive disorders (MDD) in Thailand using escitalopram compared to fluoxetine and venlafaxine: a pharmacoeconomic evaluation
    Ronnachai Kongsakon
    Department of Psychiatry, Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand
    J Med Assoc Thai 91:1117-28. 2008
    ..Escitalopram earned a savings of Baht 2,002 and Baht 1,768 compared to fluoxetine and venlafaxine respectively over a six-month period...
  60. doi Venlafaxine extended release versus citalopram in patients with depression unresponsive to a selective serotonin reuptake inhibitor
    Alan J Lenox-Smith
    Wyeth UK, Huntercombe Lane South, Slough, UK
    Int Clin Psychopharmacol 23:113-9. 2008
    ..Patients who remain severely depressed following treatment with an SSRI may gain more benefit from the dual-action drug venlafaxine, rather than switching to another SSRI...
  61. ncbi Citalopram versus fluoxetine for the treatment of patients with bulimia nervosa: a single-blind randomized controlled trial
    Paolo Leombruni
    Department of Neurosciences, Section of Psychiatry University of Turin, S Giovanni Battista Hospital, Turin, Italy
    Adv Ther 23:481-94. 2006
    ..Both treatments showed some effect on outcome measures, but efficacy profiles did not overlap. Citalopram may be useful in depressed patients with bulimia, whereas fluoxetine is more specific for those with introjected anger and bulimia...
  62. doi Mouse strain differences in the unpredictable chronic mild stress: a four-antidepressant survey
    Ipek Yalcin
    Universite Francois Rabelais de Tours, France
    Behav Brain Res 193:140-3. 2008
    ..In conclusion, these results emphasize that BALB/c mice are more sensitive than Swiss mice for studying the effects of the UCMS model as well as for testing antidepressant-like properties...
  63. doi Serotonin syndrome: a complex but easily avoidable condition
    Yael Dvir
    Department of Psychiatry, University of Massachusetts Medical School, Worcester, MA 01655, USA
    Gen Hosp Psychiatry 30:284-7. 2008
    ..The following case highlights the complex nature in which serotonin syndrome can arise, as well as the proper recognition and treatment of a potentially life-threatening yet easily avoidable condition...
  64. ncbi The role of IL-12 and TGF-beta1 in the pathophysiology of major depressive disorder
    Kyung Min Lee
    Department of Psychiatry, Korea University College of Medicine, Ansan Hospital, Go Jan Dong, Ansan City, Kyunggi Province, Seoul 425 070, South Korea
    Int Immunopharmacol 6:1298-304. 2006
    ..These findings suggest that major depression is accompanied by immune activation during the acute depressed state, and antidepressant treatments have anti-inflammatory effects...
  65. ncbi Switching patients from daily citalopram, paroxetine, or sertraline to once-weekly fluoxetine in the maintenance of response for depression
    Cherri M Miner
    Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Ind 46285, USA
    J Clin Psychiatry 63:232-40. 2002
    ....
  66. ncbi Maintenance treatment of depression in old age
    Jonathan L Edwards
    N Engl J Med 354:2505-6; author reply 2505-6. 2006
  67. ncbi Substitution of an SSRI with bupropion sustained release following SSRI-induced sexual dysfunction
    A H Clayton
    Department of Psychiatric Medicine, University of Virginia, Charlottesville 22903, USA
    J Clin Psychiatry 62:185-90. 2001
    ..Results show that sexual functioning improves after the addition of bupropion SR to SSRI treatment and continues to improve, after discontinuation of the SSRI, with bupropion SR treatment alone...
  68. ncbi Bupropion: a review of its use in the management of major depressive disorder
    Sohita Dhillon
    Wolters Kluwer Health, Adis, Auckland, New Zealand
    Drugs 68:653-89. 2008
    ..Available clinical data suggest that bupropion is an effective and generally well tolerated option in the treatment of MDD, with the newer formulations having the advantage of reduced frequency of daily administration...
  69. doi [A clinical challenge. Pragmatic treatment of migraine and concomitant depression]
    T P Jürgens
    Klinik fur Psychiatrie, Universitat Regensburg, Universitatsstrasse 84, 93053, Regensburg, Germany
    Schmerz 22:11-6. 2008
    ..Additionally, hazardous interactions and preferable drug combinations are listed...
  70. ncbi Benefits and harms of pediatric antidepressant medications
    Jonathan L Edwards
    JAMA 298:626-7; author reply 627. 2007
  71. ncbi [New developments in hypericum extracts: data on efficacy and interactions]
    Karin Kraft
    Klinik und Poliklinik für Innere Medizin, Lehrstuhl für Naturheilkunde, Rostock, Germany
    Wien Med Wochenschr 157:284-7. 2007
    ..The main compound responsible for interactions is presumably hyperforin, but further ingredients could contribute according to the specific composition of the particular extract...
  72. ncbi Increased sensitivity to antidepressants of D3 dopamine receptor-deficient mice in the forced swim test (FST)
    Gian Marco Leggio
    Department of Experimental and Clinical Pharmacology, University of Catania Medical School, 95125 Catania, Italy
    Eur Neuropsychopharmacol 18:271-7. 2008
    ....
  73. ncbi An open-label trial of aripiprazole augmentation for treatment-resistant generalized anxiety disorder
    Matthew A Menza
    J Clin Psychopharmacol 27:207-10. 2007
  74. ncbi A randomized, single-blind, comparison of venlafaxine with paroxetine in elderly patients suffering from resistant depression
    Doron Mazeh
    Abarbanel Mental Health Center, Bat Yam, Israel
    Int Clin Psychopharmacol 22:371-5. 2007
    ..Elderly depressed patients resistant to previous treatments had responded to a trial of paroxetine or venlafaxine. Remission rates were higher for venlafaxine and tolerability was acceptable for both compounds...
  75. ncbi [A place for SSRIs in the treatment of severely depressed children and adolescents]
    T H Roobol
    Karakter, Universitair Centrum voor Kinder en Jeugdpsychiatrie, Reinier Postlaan 12, 6525 GC Nijmegen
    Ned Tijdschr Geneeskd 152:1710-2. 2008
    ..Children with severe depression or a depression not responding to psychological therapy can be treated with SSRIs. Fluoxetine is the treatment of first choice...
  76. ncbi Effects of citalopram and fluoxetine on the corticocerebral blood flow in conscious rabbits
    K Sas
    Department of Neurology, University of Szeged, P O Box 427, H 6701 Szeged, Semmelweis u 6, H 6725 Szeged, Hungary
    Acta Physiol Hung 94:167-77. 2007
    ..Besides enhancement of the serotonergic transmission in the brain, the cCBF-increasing effect of citalopram under ischemic conditions may be of benefit in post-stroke and vascular depression...
  77. ncbi Effect of fluoxetine on circadian rhythm of melatonin in patients with major depressive disorder
    Zhong Lin Tan
    Hefei National Laboratory for Physical Sciences at Microscale and Department of Neurobiology, School of Life Science, University of Science and Technology of China, China
    Neuro Endocrinol Lett 28:28-32. 2007
    ..The purpose of this study is to explore the response of melatonin circadian rhythm to fluoxetine treatment and its relationship with clinical therapeutic effect...
  78. ncbi Antidepressant use and off-label prescribing in children and adolescents in Dutch general practice (2001-2005)
    Anita C Volkers
    NIVEL, Utrecht, The Netherlands
    Pharmacoepidemiol Drug Saf 16:1054-62. 2007
    ..To study the use of antidepressants in children and adolescents in Dutch general practice in 2001 and 2005 and to determine off-label prescribing...
  79. ncbi [Use of antidepressants among children and adolescents--did the warnings lead to fewer prescriptions?]
    Jørgen G Bramness
    Avdeling for legemiddelepidemiologi, Divisjon for epidemiologi, Nasjonalt folkehelseinstitutt, Postboks 4404 Nydalen, 0403 Oslo
    Tidsskr Nor Laegeforen 127:2653-5. 2007
    ..The newly established Norwegian Prescription Database was used to investigate whether these warnings have had an effect...
  80. ncbi Escitalopram versus venlafaxine XR in the treatment of depression
    Stuart A Montgomery
    Imperial College School of Medicine, University of London, London, UK
    Int Clin Psychopharmacol 21:297-309. 2006
    ..2% in the venlafaxine XR group. The mean number of discontinuation emergent signs and symptoms in the venlafaxine XR group (mean: 5.0) was significantly (P<0.001) higher than for the escitalopram group (mean: 2.4)...
  81. ncbi [Serotonin reuptake inhibitors in depression of Alzheimer's disease and other dementias]
    Florence Lebert
    Centre Médical des Monts de Flandres, Centre de la Mémoire, CHRU Lille, Bailleul
    Presse Med 32:1181-6. 2003
    ....
  82. ncbi Do venlafaxine XR and paroxetine equally influence negative and positive affect?
    Gabriel S Dichter
    Department of Psychology, College of Arts and Sciences, Wilson Hall, Vanderbilt University, Nashville TN 37203, USA
    J Affect Disord 85:333-9. 2005
    ....
  83. ncbi Discontinuation rates for selective serotonin reuptake inhibitors and other second-generation antidepressants in outpatients with major depressive disorder: a systematic review and meta-analysis
    Gerald Gartlehner
    Cecil G Sheps Center for Health Services Research, University of North Carolina, Chapel Hill, NC 27599, USA
    Int Clin Psychopharmacol 20:59-69. 2005
    ....
  84. ncbi Bupropion in the treatment of outpatients with asthma and major depressive disorder
    E Sherwood Brown
    Department of Psychiatry, University of Texas Southwestern Medical Center at Dallas, 75390 8849, USA
    Int J Psychiatry Med 37:23-8. 2007
    ..The objective of this pilot study was to investigate the use of bupropion for depression and anxiety in depressed asthma patients...
  85. ncbi Geriatric depression treatment in nonresponders to selective serotonin reuptake inhibitors
    Ellen M Whyte
    Department of Psychiatry, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA
    J Clin Psychiatry 65:1634-41. 2004
    ....
  86. ncbi Selective serotonin reuptake inhibitor usage patterns as risk factors for hospitalization
    Reinée E Sheffield
    PCS Health Systems, Scottsdale, AZ, USA
    Adm Policy Ment Health 30:121-39. 2002
    ..However, initiation on paroxetine or sertraline rather than fluoxetine may increase the risk of hospitalization among patients not exhibiting a stable usage pattern...
  87. ncbi Fluoxetine-induced memory impairment in four family members
    Shu Chi Huang
    Department of Psychiatry, Chung Shan Medical University Hospital, Taiwan, R O C
    Int J Psychiatry Med 34:197-200. 2004
    ..Fluoxetine, a selective serotonin reuptake inhibitor antidepressant agent, has been implicated in learning and memory. Here, we report four cases from the same family of fluoxetine-related memory-impairment...
  88. ncbi Fluoxetine, cognitive-behavioral therapy, and their combination for adolescents with depression: Treatment for Adolescents With Depression Study (TADS) randomized controlled trial
    John March
    Duke Clinical Research Institute, Department of Psychiatry, Duke University Medical Center, Durham, NC 27710, USA
    JAMA 292:807-20. 2004
    ..Initial treatment of major depressive disorder in adolescents may include cognitive-behavioral therapy (CBT) or a selective serotonin reuptake inhibitor (SSRI). However, little is known about their relative or combined effectiveness...
  89. ncbi Continuation cognitive-behavioural therapy maintains attributional style improvement in depressed patients responding acutely to fluoxetine
    T Petersen
    Depression Clinical and Research Program, Massachusetts General Hospital, Boston, MA, USA
    Psychol Med 34:555-61. 2004
    ..The goal of this study was to examine whether CBT would help maintain attributional style changes experienced by patients during acute phase fluoxetine treatment...
  90. ncbi Sertraline versus fluoxetine in the treatment of major depression: a combined analysis of five double-blind comparator studies
    Alan D Feiger
    Feiger Health Research Center, Wheat Ridge, Colorado 80033, USA
    Int Clin Psychopharmacol 18:203-10. 2003
    ..16) in the anxious-depression subgroup. Overall, sertraline and fluoxetine showed comparable antidepressant efficacy, although sertraline may offer an advantage in those patients with severe depression...
  91. ncbi Combining bupropion SR with venlafaxine, paroxetine, or fluoxetine: a preliminary report on pharmacokinetic, therapeutic, and sexual dysfunction effects
    Sidney H Kennedy
    Centre for Addiction and Mental Health, and the Department of Psychiatry, University of Toronto, Ontario, Canada
    J Clin Psychiatry 63:181-6. 2002
    ....
  92. ncbi Antidepressant medications in children
    Benedetto Vitiello
    National Institute of Mental Health, Bethesda, MD, USA
    N Engl J Med 350:1489-91. 2004
  93. ncbi Combining norepinephrine and serotonin reuptake inhibition mechanisms for treatment of depression: a double-blind, randomized study
    J Craig Nelson
    Department of Psychiatry, University of California San Francisco, 401 Parnassus Avenue, Box 0984 5, San Francisco, CA 94143, USA
    Biol Psychiatry 55:296-300. 2004
    ..The current study was undertaken as a proof of the concept that combining norepinephrine and serotonin reuptake inhibition would be more effective and act more rapidly than either drug alone...
  94. ncbi Switching to bupropion in fluoxetine-resistant major depressive disorder
    Maurizio Fava
    The Depression Clinical and Research Program, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts 02114, USA
    Ann Clin Psychiatry 15:17-22. 2003
    ..Bupropion SR should be considered as a potential treatment for patients who remain depressed despite treatment with SSRIs..
  95. ncbi The validity of the depression rating scales in discriminating between citalopram and placebo in depression recurrence in the maintenance therapy of elderly unipolar patients with major depression
    J Bent-Hansen
    Psychiatric Research Clinic, Frederiksberg Hospital
    Pharmacopsychiatry 36:313-6. 2003
    ..In future trials on the recurrence prevention of unipolar depression, a cutoff score of 25 rather than 22 on the MADRS is recommended...
  96. ncbi Antidepressant monotherapy for bipolar type II major depression
    Jay D Amsterdam
    Department of Psychiatry, Depression Research Unit, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA
    Bipolar Disord 5:388-95. 2003
    ..Recent studies have provided evidence that antidepressant monotherapy may be an effective initial and long-term treatment for BP II major depression with a low manic-switch rate...
  97. ncbi [Obsessive-compulsive disorders in general practice. How the obsessive-compulsive neurotic is revealed by skin and hair]
    A Kordon
    Klinik fur Psychiatrie und Psychotherapie, Universitatsklinikum Schleswig Holstein, Campus Lubeck
    MMW Fortschr Med 145:4-7. 2003
    ..This reduces distress, disability and burden of illness. Pharmacological treatment with serotonin reuptake inhibitors (SRI) and cognitive-behavioral therapy have both been proven to be effective and are evidence based...
  98. pmc Effects of acute treatment with paroxetine, citalopram and venlafaxine in vivo on noradrenaline and serotonin outflow: a microdialysis study in Swiss mice
    D J P David
    EA 3544, Lab Neuropharmacologie, Faculte de Pharmacie, Universite Paris Sud, Châtenay Malabry 92296, France
    Br J Pharmacol 140:1128-36. 2003
    ..Surprisingly, the SNRI venlafaxine increased cortical [5-HT]ext to a greater extent rather than [NA]ext in the range of doses studied in mice...
  99. ncbi [Review of antidepressants from the TCAs to the third generation drugs]
    János Almási
    Organon Hungary Kft, Orvosi Osztály, Budapest
    Neuropsychopharmacol Hung 6:185-94. 2004
    ..The main aim of this review is to give an objective approach to the psychiatrists in order to choose the best and optimal pharmaco-therapeutical method in their daily practice...
  100. ncbi Clinical practice guidelines for depression in young people
    Jon N Jureidini
    Med J Aust 178:300; author reply 300-2. 2003
  101. ncbi Influence of monoamine oxidase A and serotonin receptor 2A polymorphisms in SSRI antidepressant activity
    Cristina Cusin
    Department of Psychiatry, Vita Salute University, Raffaele del Monte Tabor, Milan, Italy
    Int J Neuropsychopharmacol 5:27-35. 2002
    ..The investigated MAOA and 5-HT-2A gene variants, therefore, do not seem to play a major role in SSRI antidepressant activity...

Research Grants144 found, 100 shown here

  1. Chamomile therapy for generalized anxiety disorder
    Jay Amsterdam; Fiscal Year: 2006
    ....
  2. 1/2-Prevention of Relapse & Recurrence of Bipolar Depression
    Jay D Amsterdam; Fiscal Year: 2010
    ..Results from this study may also inform new research hypotheses for future trials in BP I disorder. ..
  3. 1/2-Ziprasidone Augmentation of SSRIs for Treatment-Resistant Depression (TRD)
    George Papakostas; Fiscal Year: 2009
    ..We estimate that 180 of these patients will enter the double-blind phase. ..
  4. 1/2-Ziprasidone Augmentation of SSRIs for Treatment-Resistant Depression (TRD)
    George I Papakostas; Fiscal Year: 2010
    ..We estimate that 180 of these patients will enter the double-blind phase. ..
  5. SPECT Brain Imaging as a Biomarker of Major Depression
    Jay Amsterdam; Fiscal Year: 2007
    ..We will compare these results to measurements of striatal DAT levels in 22 non-depressed, healthy subjects studied under similar conditions with [99mTc]TRODAT-1 SPECT on two separate occasions 8 weeks apart. ..
  6. Long-Term Chamomile Therapy of Generalized Anxiety Disorder
    Jay D Amsterdam; Fiscal Year: 2010
    ..It also found chamomile to be well tolerated. The present application will extend these promising results by studying the long-term benefit of chamomile in preventing relapse of anxiety. ..
  7. RELAPSE PREVENTION OF BIPOLAR TYPE-II DISORDER
    Jay Amsterdam; Fiscal Year: 2005
    ..We believe that our study has the potential to have a significant impact upon current clinical practice in the appropriate management of bipolar depressed patients; an extremely important public-health matter. ..
  8. Treatment of Bipolar Type II Major Depression
    Jay D Amsterdam; Fiscal Year: 2010
    ..If our hypotheses are correct, we believe that these results may have an important public health impact on the current practice guidelines for treating BP II MDE. ..
  9. Treatment of Bipolar Type II Major Depression
    Jay Amsterdam; Fiscal Year: 2007
    ..If our hypotheses are correct, we believe that these results may have an important public health impact on the current practice guidelines for treating BP II MDE. ..
  10. Black cohosh therapy for menopause-related anxiety
    Jay Amsterdam; Fiscal Year: 2006
    ..We hypothesize that Black Cohosh will result in superior QOL measures compared to placebo. ..
  11. 1/2-Prevention of Relapse & Recurrence of Bipolar Depression
    Jay Amsterdam; Fiscal Year: 2009
    ..Results from this study may also inform new research hypotheses for future trials in BP I disorder. ..
  12. Long-Term Chamomile Therapy of Generalized Anxiety Disorder
    Jay Amsterdam; Fiscal Year: 2009
    ..It also found chamomile to be well tolerated. The present application will extend these promising results by studying the long-term benefit of chamomile in preventing relapse of anxiety. ..
  13. Development of an Inventory of Depressive Symptomatology
    AUGUSTUS RUSH; Fiscal Year: 2005
    ..g., anxiety, irritability) (IDS-C and SR) that are in the public domain for use with patients across the age spans seen in practice and in research. ..
  14. CANCER CHEMOPREVENTION--ROLE OF INFECTION/IMMUNITY
    Charles Loprinzi; Fiscal Year: 2003
    ..abstract_text> ..
  15. 3/3-Efficacy and Tolerability of Riluzole in Treatment-Resistant Depression
    Maurizio Fava; Fiscal Year: 2010
    ....
  16. Special Scientific Procedures: Statistical Modeling Core
    Charles Nemeroff; Fiscal Year: 2007
    ..abstract_text> ..
  17. COMMUNITY CLINICAL ONCOLOGY PROGRAM
    Charles Loprinzi; Fiscal Year: 2006
    ..abstract_text> ..
  18. Drug Discovery Group for Nicotine Dependence Treatment
    Maurizio Fava; Fiscal Year: 2007
    ..Each organization will make a unique contribution of personnel and resources to the implementation and success of the project. ..
  19. Controlled Study of SAMe vs.Escitalopram in Major Depressive Disorder
    Maurizio Fava; Fiscal Year: 2007
    ..Secondary aims are to assess the acute effects of SAMe or escitalopram vs. placebo on remission rates, quality of life, and psychosocial functioning. ..
  20. Emory-GSK-NIMH Collaborative Mood Disorders Initiative
    Clinton Kilts; Fiscal Year: 2007
    ..abstract_text> ..
  21. CAPITATION
    Charles Loprinzi; Fiscal Year: 2007
    ..Funding is requested for this submission to support 375 total accruals at all non-CCOP NCCTG sites at the current rate of $2,000 each, for a total request of $750,000. ..
  22. BUPROPION AS AN ADJUNCT TO THE NICOTINE PATCH PLUS CBT
    Maurizio Fava; Fiscal Year: 2003
    ....
  23. TREATMENT OF SSRI-RESISTANT DEPRESSION IN ADOLESCENTS
    Martin Keller; Fiscal Year: 2006
    ..This site is based in Pittsburgh, which also serves as the Data Coordinating Center for the study ..
  24. Citicoline for Bipolar Disorder and Cocaine Dependence
    E Sherwood Brown; Fiscal Year: 2010
    ..To conduct this trial we have assembled a research team with expertise in mood disorders, clinical trials, cocaine dependence, neuropsychological testing, and statistical analysis. ..
  25. Harvard/Brown Anxiety Program (HARP)
    Martin Keller; Fiscal Year: 2009
    ....
  26. TREATMENT OF SSRI-RESISTANT DEPRESSION IN ADOLESCENTS
    Graham Emslie; Fiscal Year: 2006
    ..This site is based in Pittsburgh, which also serves as the Data Coordinating Center for the study ..
  27. Pediatric MDD: Sequential Treatment with Fluoxetine and Relapse Prevention CBT
    Beth D Kennard; Fiscal Year: 2010
    ....
  28. Building a Risk Stratification Model for Treatment Resistance in Major Depressive
    Roy H Perlis; Fiscal Year: 2010
    ..Then, it will examine a second group of patients to see how well this technique might work if it is applied in a large health system. ..
  29. Pramipexole in Treatment-Resistant Depression
    Roy Perlis; Fiscal Year: 2007
    ..The proposed investigation and training program will provide critical skills, experience and data to aid the candidate in writing an R01 and becoming an independent investigator. ..
  30. RESEARCH TRAINING: PSYCHOBIOLOGICAL SCIENCES
    Andrew Leuchter; Fiscal Year: 2007
    ..The University is providing financial support for this predoctoral training program. These changes should lead to an enhanced training experience for a more diverse group of postdoctoral and predoctoral trainees. ..
  31. Psychobiologic Factors of the Placebo Response in MDD
    Andrew Leuchter; Fiscal Year: 2007
    ..The results of this project will lead to better understanding of the mechanisms of the placebo response in MDD. ..
  32. Pediatric MDD: Sequential Treatment with Fluoxetine and Relapse Prevention CBT
    Graham Emslie; Fiscal Year: 2009
    ....
  33. Treatment of Adolescent Suicide Attempters in Dallas
    Graham Emslie; Fiscal Year: 2006
    ..This exemplary protocol stimulated the formation of a collaborative group of 8 RUPP-PI applicants. By creating the protocol, the group forged an ability to work together. ..
  34. Child Psychiatry Research Education Program (C-PREP)
    Graham Emslie; Fiscal Year: 2007
    ....
  35. CHILDHOOD DEPRESSION: REMISSION AND RELAPSE
    Graham Emslie; Fiscal Year: 2004
    ..The primary outcome variable will be response to acute treatment and relapse during continuation phase treatment. There have been no studies of need for continuation treatment in depression in the pediatric age group. ..
  36. CHILDHOOD DEPRESSION-BIOLOGICAL CORRELATES
    Graham Emslie; Fiscal Year: 1993
    ..Clinically antidepressants are widely used in treatment of depression in this age group and yet controlled studies are limited. If medication is effective in some then it would be important to determine in whom...
  37. ENHANCING TREATMENT OUTCOMES IN DEPRESSION
    Andrew Leuchter; Fiscal Year: 2004
    ..These effectiveness projects will include introduction of predictors into the usual treatment setting, and examination of cost-effectiveness and long-term treatment outcomes. ..
  38. Treatment of Early Age Mania (TEAM)
    Graham Emslie; Fiscal Year: 2003
    ..D. (4) University of Texas, Dallas, PI: Graham Emslie, M.D. (5) University of Texas, Galveston, PI: Karen Dineen Wagner, M.D. and (6) Washington University, St. Louis, PI; Joan Luby, M.D. ..
  39. PROPHYLACTIC COGNITIVE THERAPY FOR DEPRESSION
    Michael Thase; Fiscal Year: 2007
    ....
  40. PROPHYLACTIC COGNITIVE THERAPY FOR DEPRESSION
    Michael Thase; Fiscal Year: 2004
    ..Blind evaluations occur at the end of the acute phase and at four and eight months post-acute phase CT, as well as at suspected relapse or exit. Survival analyses are planned. ..
  41. PROPHYLACTIC COGNITIVE THERAPY FOR DEPRESSION
    Michael Thase; Fiscal Year: 2009
    ....
  42. PROPHYLACTIC COGNITIVE THERAPY FOR DEPRESSION
    Michael Thase; Fiscal Year: 2005
    ..Specifically, if C-CT is significantly more effective than PBO at the end of "Phase 1," then FLX must also have therapeutic activity. ..